Terms: = Prostate cancer AND ZBTB16, Q05516, 7704, ENSG00000109906, ZNF145, PLZF
22 results:
1. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract] [Full Text] [Related]
2. Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4.
Dahal S; Chaudhary P; Kim JA
Cell Oncol (Dordr); 2023 Aug; 46(4):1113-1126. PubMed ID: 36995683
[TBL] [Abstract] [Full Text] [Related]
3. Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of PDGFB via the plzf-mediated recruitment of EZH2.
Han H; Wang S; Meng J; Lyu G; Ding G; Hu Y; Wang L; Wu L; Yang W; Lv Y; Jia S; Zhang L; Ji J
Oncogene; 2020 Oct; 39(42):6513-6528. PubMed ID: 32901105
[TBL] [Abstract] [Full Text] [Related]
4. The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.
Ramanand SG; Chen Y; Yuan J; Daescu K; Lambros MB; Houlahan KE; Carreira S; Yuan W; Baek G; Sharp A; Paschalis A; Kanchwala M; Gao Y; Aslam A; Safdar N; Zhan X; Raj GV; Xing C; Boutros PC; de Bono J; Zhang MQ; Mani RS
J Clin Invest; 2020 Aug; 130(8):3987-4005. PubMed ID: 32343676
[TBL] [Abstract] [Full Text] [Related]
5. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in prostate cancer.
Han D; Chen S; Han W; Gao S; Owiredu JN; Li M; Balk SP; He HH; Cai C
Cancer Res; 2019 Oct; 79(20):5260-5271. PubMed ID: 31444154
[TBL] [Abstract] [Full Text] [Related]
6. Low Expression of the Androgen-Induced Tumor Suppressor Gene
Stopsack KH; Gerke T; Tyekucheva S; Mazzu YZ; Lee GM; Chakraborty G; Abida W; Mucci LA; Kantoff PW
Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):707-714. PubMed ID: 30602500
[TBL] [Abstract] [Full Text] [Related]
7. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
[TBL] [Abstract] [Full Text] [Related]
8. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for prostate cancer.
Chiu PK; Alberts AR; Venderbos LDF; Bangma CH; Roobol MJ
BJU Int; 2017 Sep; 120(3):394-400. PubMed ID: 28498624
[TBL] [Abstract] [Full Text] [Related]
9. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant prostate cancer Growth.
Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
[TBL] [Abstract] [Full Text] [Related]
10. Integrative clinical genomics of advanced prostate cancer.
Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
[TBL] [Abstract] [Full Text] [Related]
11. Loss of plzf expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.
Xiao GQ; Unger P; Yang Q; Kinoshita Y; Singh K; McMahon L; Nastiuk K; Sha K; Krolewski J; Burstein D
PLoS One; 2015; 10(3):e0121318. PubMed ID: 25807461
[TBL] [Abstract] [Full Text] [Related]
12. Downregulation of plzf in human hepatocellular carcinoma and its clinical significance.
Hui AW; Lau HW; Cao CY; Zhou JW; Lai PB; Tsui SK
Oncol Rep; 2015 Jan; 33(1):397-402. PubMed ID: 25369784
[TBL] [Abstract] [Full Text] [Related]
13. Enrichment of spermatogonial stem cells from long-term cultured human testicular cells.
Nickkholgh B; Mizrak SC; Korver CM; van Daalen SK; Meissner A; Repping S; van Pelt AM
Fertil Steril; 2014 Aug; 102(2):558-565.e5. PubMed ID: 24864010
[TBL] [Abstract] [Full Text] [Related]
14. plzf mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis.
Cao J; Zhu S; Zhou W; Li J; Liu C; Xuan H; Yan J; Zheng L; Zhou L; Yu J; Chen G; Huang Y; Yu Z; Feng L
PLoS One; 2013; 8(12):e77922. PubMed ID: 24339862
[TBL] [Abstract] [Full Text] [Related]
15. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.
Jin Y; Qu S; Tesikova M; Wang L; Kristian A; Mælandsmo GM; Kong H; Zhang T; Jerónimo C; Teixeira MR; Yuca E; Tekedereli I; Gorgulu K; Alpay N; Sood AK; Lopez-Berestein G; Danielsen HE; Ozpolat B; Saatcioglu F
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):E2572-81. PubMed ID: 23798432
[TBL] [Abstract] [Full Text] [Related]
16. Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression.
van de Wijngaart DJ; Dubbink HJ; Molier M; de Vos C; Trapman J; Jenster G
Mol Endocrinol; 2009 Nov; 23(11):1776-86. PubMed ID: 19762545
[TBL] [Abstract] [Full Text] [Related]
17. Nuclear LYRIC/AEG-1 interacts with plzf and relieves plzf-mediated repression.
Thirkettle HJ; Mills IG; Whitaker HC; Neal DE
Oncogene; 2009 Oct; 28(41):3663-70. PubMed ID: 19648967
[TBL] [Abstract] [Full Text] [Related]
18. plzf regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S
Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071
[TBL] [Abstract] [Full Text] [Related]
19. Silencing of androgen-regulated genes using a fusion of AR with the plzf transcriptional repressor.
Pike J; Holmes D; Kamalati T; Davies D; Tolhurst R; Mazhar D; Fishpool S; al-Jehani R; Waxman J; Zelent A; Lemoine NR; Ali S; Buluwela L
Oncogene; 2004 Sep; 23(45):7561-70. PubMed ID: 15334066
[TBL] [Abstract] [Full Text] [Related]
20. Identification and characterization of plzf as a prostatic androgen-responsive gene.
Jiang F; Wang Z
Prostate; 2004 Jun; 59(4):426-35. PubMed ID: 15065091
[TBL] [Abstract] [Full Text] [Related]
[Next]
